Phio Pharmaceuticals Corp. (PHIO) Dividend History

Company News

• Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033

  The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.

  GlobeNewswire Inc.

  Featured Companies: BAX BMY JNJ LLY MRK PFE RCUS REGN
• Phio Pharmaceuticals Secures New Investor

  --Fund invests in microcap equities --Fund invests in microcap equities

  GlobeNewswire Inc.
• Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

  -PH-762 is Phio’s lead product candidate

  GlobeNewswire Inc.
• Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

  –Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762

  GlobeNewswire Inc.
• Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

  -Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation -Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation

  GlobeNewswire Inc.